Pages that link to "Q42930914"
Jump to navigation
Jump to search
The following pages link to Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy (Q42930914):
Displaying 16 items.
- Investigating the Generalizability of Economic Evaluations Conducted in Italy: A Critical Review (Q26795684) (← links)
- Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available (Q31061574) (← links)
- Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews (Q33814897) (← links)
- A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC) (Q34727967) (← links)
- Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review (Q34742887) (← links)
- Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC). (Q36138536) (← links)
- Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents (Q36765647) (← links)
- Tumor control versus adverse events with targeted anticancer therapies (Q37969899) (← links)
- Pemetrexed for the treatment of non-small cell lung cancer. (Q38107552) (← links)
- Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany (Q42930912) (← links)
- Treatment of lung cancer: will financial issues become a criterion of choice? (Q45833913) (← links)
- Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature (Q50238133) (← links)
- Cost‐effectiveness of bevacizumab‐based therapy versus cisplatin plus pemetrexed for the first‐line treatment of advanced non‐squamous NSCLC in Korea and Taiwan (Q57226496) (← links)
- A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Nonsquamous Non-Small-Cell Lung Cancer in China (Q58609054) (← links)
- Antiangiogeneic Strategies in Mesothelioma (Q90056612) (← links)
- Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer (NSCLC) (Q101559633) (← links)